1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies

 
• By Reed Miller

Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.

Medical monitor with green lines of an abnormal ECG showing atrial fibrillation, a red line for the arterial blood pressure and a blue line for the oxygen saturation against a black background.
• Source: shutterstock.com

Johnson & Johnson/Biosense Webster Inc is sponsoring the inspIRE study of its Varipulse pulsed field ablation catheter with the Trupulse generator for treating recurrent paroxysmal atrial fibrillation (AF).

Cardiac ablation blocks the electrical signals that cause an arrythmia by creating focused scars in the cardiac tissue, usually by heating the tissue with radiofrequency

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

No Knife, No Burn, Just Bubbles: HistoSonics Hits 90% Tumor Control In #HOPE4Liver Trial, Eyes IPO Timing

 
• By Marion Webb

HistoSonics, which developed a noninvasive technology to destroy tumor cells, reports 90% local tumor control at 12-month follow-up in the #HOPE4Liver Trial. The Edison System, cleared by the US FDA in late 2023, is also being evaluated for kidney and pancreatic tumors. CEO Mike Blue said the medtech is financially secure but watching public markets as it considers an IPO.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

First Liver Cancer Surveillance Test In Five Years Receives FDA Breakthrough Status

 
• By Natasha Barrow

Cambridge-based startup Mursla Bio's liquid biopsy test EvoLiver uses extracellular vesicles to detect hepatocellular carcinoma (HCC) in high-risk cirrhotic patients. Medtech Insight sat down with with Mursla Bio CEO Pierre Arsène.